Showing results (201-210 of 453) with videos related to
Sort By:
Pageof 46
Cancer Chemotherapy and Pharmacology|December 27, 2015
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patientsRajiv Kumar, Shir Kiong Lu, Anna Minchom, et al.British Journal of Cancer|May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumoursGeoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1Anthony W Tolcher, John Sarantopoulos, Amita Patnaik, et al.Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.European Journal of Cancer (Oxford, England : 1990)|December 26, 2012
Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancerDavid S P Tan, Timothy A Yap, Margaret Hutka, et al.Neuro-Oncology Advances|March 19, 2021
The promise of DNA damage response inhibitors for the treatment of glioblastomaNazanin K Majd, Timothy A Yap, Dimpy Koul, et al.Genome Medicine|March 30, 2018
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterationsDavid Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and BiomarkersOlanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, et al.The Oncologist|August 10, 2019
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF AlterationsAditya Bardia, Mrinal Gounder, Jordi Rodon, et al.Transboundary and Emerging Diseases|October 2, 2020
Pigs are not susceptible to SARS-CoV-2 infection but are a model for viral immunogenicity studiesJúlia Vergara-Alert, Jordi Rodon, Jorge Carrillo, et al.Pageof 46